TRIMPEX 200
LOE ApproachingNDAORALTABLET
Approved
May 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIMPEX 200 is an oral tablet NDA approved by Roche in 1980 with an unknown mechanism of action and indication profile. The specific therapeutic area and patient population cannot be determined from available data.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating team focus is likely on transition planning and lifecycle extension strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings and approaching LOE indicate this product is not a growth career opportunity. Roles available would focus on defending market share, managing decline, and transitioning patients to successor therapies.
Brand ManagerField Sales
Worked on TRIMPEX 200 at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.